Jeffrey Tyner

Assistant Professor

Oregon Health & Science University

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jeffrey Tyner is an Assistant Professor at Oregon Health and Science University in the United States. His research focuses on hematologic malignancies, particularly acute myeloid leukemia, investigating genetic and phenotypic correlates of clinical outcomes and acquired resistance mechanisms. His recent publications explore innovative therapeutic strategies and multiomic profiling to enhance patient outcomes across diverse populations.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (10)

Emmanuel Olivier

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Anbarasu Kumaraswamy

University of Michigan

UNITED STATES

View details

Irum Khan

University of Illinois System

UNITED STATES

View details

Shannon McWeeney

Professor and Vice Chair

Oregon Health & Science University

UNITED STATES

View details

Maarten Fornerod

Associate professor

Erasmus MC

NETHERLANDS

View details

Deedra Nicolet

Ohio State University

UNITED STATES

View details

Monika Davare

Oregon Health & Science University

UNITED STATES

View details

Daniel Peters

Assistant Professor

Augusta University

UNITED STATES

View details

Yusuke Nakauchi

Stanford University

UNITED STATES

View details

H. Leighton Grimes

Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jeffrey Tyner

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML

Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.

Acquired resistance in cancer: towards targeted therapeutic strategies

Identifying Drug Combination Strategies for <i>ZMYM2: FGFR1</i> Fusion Positive Leukemia.

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia.

Oncogenic <i>NTRK3</i> mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia.

Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Understanding Drug Sensitivity and Tackling Resistance in Cancer

Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia

Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

Collaborators (10)

Emmanuel Olivier

Anbarasu Kumaraswamy

Irum Khan

Shannon McWeeney

Maarten Fornerod

Deedra Nicolet

Monika Davare

Daniel Peters

Yusuke Nakauchi

H. Leighton Grimes

Make your next move.

Jeffrey Tyner

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML

Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.

Acquired resistance in cancer: towards targeted therapeutic strategies

Identifying Drug Combination Strategies for &lt;i&gt;ZMYM2: FGFR1&lt;/i&gt; Fusion Positive Leukemia.

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia.

Oncogenic &lt;i&gt;NTRK3&lt;/i&gt; mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia.

Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Understanding Drug Sensitivity and Tackling Resistance in Cancer

Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia

Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

Collaborators (10)

Emmanuel Olivier

Anbarasu Kumaraswamy

Irum Khan

Shannon McWeeney

Maarten Fornerod

Deedra Nicolet

Monika Davare

Daniel Peters

Yusuke Nakauchi

H. Leighton Grimes

Make your next move.

Identifying Drug Combination Strategies for <i>ZMYM2: FGFR1</i> Fusion Positive Leukemia.

Oncogenic <i>NTRK3</i> mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia.